Ductal Carcinoma of the Prostate: An Uncommon Entity With Atypical Behaviour

Ductal adenocarcinoma is a rare variant of prostate cancer, and as such clinical outcomes and best management are not well defined. This series demonstrates the atypical presentation and unusual clinical behaviour of ductal adenocarcinoma and proposes management guidelines to assist clinicians. A re...

Full description

Saved in:
Bibliographic Details
Published in:Clinical oncology (Royal College of Radiologists (Great Britain)) 2019-02, Vol.31 (2), p.108-114
Main Authors: Bergamin, S., Eade, T., Kneebone, A., Kench, J.G., Sved, P., Biset, J.-F., Hruby, G.
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Carcinoma, Ductal
Clinical recurrence
ductal carcinoma
follow-up
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
prostate
Prostatic Neoplasms
radiotherapy
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ductal adenocarcinoma is a rare variant of prostate cancer, and as such clinical outcomes and best management are not well defined. This series demonstrates the atypical presentation and unusual clinical behaviour of ductal adenocarcinoma and proposes management guidelines to assist clinicians. A retrospective review of pure (nine patients) and mixed (18 patients) ductal adenocarcinoma of the prostate referred to the Departments of Radiation Oncology of the Sydney Cancer Centre, Royal Prince Alfred Hospital and Northern Sydney Cancer Centre, Royal North Shore Hospital, between 2000 and 2015. Twenty-seven patients were treated with definitive radiotherapy, nine patients (33%) with pure ductal and 18 (67%) with mixed ductal-acinar adenocarcinoma. The median follow-up was 38 months. Four patients (15%) failed locally, all of whom received less than 80 Gy, or no brachytherapy boost. Five patients (19%) failed distantly, four with biopsy-proven lung metastases. All distant failures occurred with a prostate-specific antigen (PSA) 
ISSN:0936-6555
1433-2981
DOI:10.1016/j.clon.2018.10.011